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Abstract
Background: δ-Catenin (CTNND2), which encodes a scaffold protein in humans, has been found in a few
malignancies. However, the expression pattern and contribution of δ-catenin to astrocytoma progression are
unclear.
Methods: We investigated δ-catenin expression in human astrocytoma samples and its function in astrocytoma
cell lines using immunohistochemistry, siRNA knockdown, transfection, MTT, transwell migration and Rac1
pulldown techniques.
Results: δ-Catenin protein expression was detected in cytoplasm of astrocytoma cells by immunohistochemistry.
Analysis showed that grade I astrocytoma (0%, 0/11) and glial cells from normal brain tissue exhibited negative
staining. δ-Catenin expression was significantly higher in grade III-IV (35%, 29/84) compared to grade II astrocytoma
cells (18%, 11/61); p < 0.01). In addition, CTNND2 overexpression promoted proliferation, invasion and Rac1 activity
of U251 astrocytoma cells. Treatment of δ-catenin-transfected cells with a Rac1 inhibitor decreased Rac1 activity
and invasion. δ-Catenin knockdown in U87 glioblastoma cell decreased cell proliferation, invasion and Rac1 activity.
Conclusion: The results suggest that δ-catenin expression is associated with the malignant progression of
astrocytoma and promotes astrocytoma cell invasion through upregulation of Rac1 activity. δ-Catenin expression
levels may serve as a useful marker of the biological behavior of astrocytoma cells.
Background
Astrocytoma arises from neural stem or progenitor cells in
the central nervous system. It is the most common primary
brain tumor and accounts for approximately 60% of all
brain tumors. Despite combined treatment strategies,
which include surgery, radiotherapy and chemotherapy, the
prognosis for high-grade astrocytoma, especially glioblas-
toma multiforme, has changed little over the past 10 years,
with a median survival of only approximately 1 year [1].
The clinical symptoms and prognosis are closely correlated
with tumor location and size and histological grade.
Although the histological grade partly reflects the malig-
nant features of astrocytoma, it cannot give an indication
of the exact mechanism of tumor invasion and recurrence
[2,3]. Thus, it is important to understand the molecular
mechanism of astrocytoma cell invasion and identify effec-
tive markers in tumorigenesis and progression.
The expression of δ-catenin was initially found to be
limited to brain neurons and it can bind to presenilin 1,
which is involved in the progression of Alzheimer’s disease
[4-6]. δ-Catenin was also implicated in the maintenance of
synaptic function and transmission of downstream signals
as a scaffold protein [7-11]. It was reported that δ-catenin
overexpression changed the morphology of MDCK cells,
including the elaboration of lamellipodia [12]. Further-
more, δ-catenin can regulate the activity of small GTPases
and therefore induces dendritic protrusions from cells
[13]. Small GTPases are critical mediators of cytoskeletal
reorganization, signal transduction and gene expression
pathways [14,15]. As one of these GTPases, Rac1 is a
pleiotropic regulator of many cellular processes, including
the cell cycle, cell-cell adhesion, motility (through the
actin network) and epithelial differentiation. δ-Catenin
also affects invasion and metastasis of lung cancer cells via
regulation of small GTPase activity [16]. These studies
suggest that δ-catenin plays an important role in many
human cancers. Our previous study showed that δ-catenin
was overexpressed in non-small-cell lung cancer and
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lation. However, the expression pattern of δ-catenin in
glial cells and human astrocytoma cells is not clear; the
relationship between its expression and clinicopathological
factors and biological behavior still needs to be addressed.
In the present study, we examined the expression of
δ-catenin in 156 astrocytoma tissue specimens and ana-
lyzed the correlation between its expression and clinico-
pathological factors. We also investigated the effect of




The study protocol was approved by the institutional
review board of China Medical University. Primary
tumor specimens and adjacent normal brain tissue were
obtained from 156 patients diagnosed with astrocytoma
who underwent resection in the First Affiliated Hospital
of China Medical University between 2005 and 2008.
None of the patients had received radiotherapy or che-
motherapy before surgical resection. There were 95 male
(60.9%) and 61 female (39.1%) patients with a median age
of 43 years (range 15-67 years). The histological diagnosis
and differentiation grade were evaluated for sections
stained with hematoxylin and eosin according to the
World Health Organization (WHO) classification guide-
lines. All 156 specimens were re-evaluated with respect
to histological subtype and tumor grade. Tumors were
graded and classified into grade I (11), grade II (61),
grade III (51), and grade IV (33) according to WHO
guidelines (2007).
Cell culture and transfection
U251 and U87 cell lines were obtained from American
Type Culture Collection (Manassas, VA, USA). The cells
were cultured in DMEM (Invitrogen, Carlsbad, CA, USA)
containing 10% fetal calf serum (Invitrogen), 100 IU/ml
penicillin (Sigma, St. Louis, MO, USA), and 100 μg/ml
streptomycin (Sigma). Cells were grown on sterilized cul-
ture dishes and were passaged every 2 days with 0.25%
trypsin (Invitrogen). The pCMV5-FLAG/δ-catenin plas-
m i dw a sak i n dg i f tf r o mD r .S h u n - i c h iN a k a m u r aa t
Kobe University and was transfected into cells using
Attractene Transfection (Qiagen, Hamburg, Germany). A
pCMV5 empty vector was used as a negative control.
DharmaFECT1 reagent was used for siRNA transfection
(Qiagen, Chicago, IL, USA) according to the manufac-
turer’s instructions. The protein level was assessed 48 h
later by western blotting. The δ-catenin siRNA sequences
were 5’- C U AC G UU G AC U UC U AC U CA U U - 3 ’ and
5’-UGA GUA GAA GUC AAC GUA GUU-3’ and were
transfected into U87 cell lines, which express relatively
high levels of δ-catenin. Nonsilencing siRNA sequences
were used as a negative control (5’-UUC UCC GAA
CUU GUC ACA UUU-3’ and 5’-AUG UGA CAA GUU
CGG AGA AUU-3’).
Immunohistochemistry
Surgically excised tumor specimens were fixed with 10%
neutral formalin and embedded in paraffin, and 4-μm-
thick sections were prepared. Normal brain neurons pre-
sent in the tumor slides was used as positive control.
Immunostaining was performed using the avidin-biotin-
peroxidase complex method (Ultrasensitive™,M a i X i n ,
Fuzhou, China). The sections were deparaffinized in
xylene, rehydrated with graded alcohol, and then boiled in
0.01 M citrate buffer (pH 6.0) for 2 min in an autoclave.
Hydrogen peroxide (0.3%) was applied to block endogen-
ous peroxide activity and the sections were incubated with
normal goat serum to reduce nonspecific binding. Tissue
sections were incubated with δ-catenin mouse monoclonal
antibody (1:100 dilution; Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Mouse immunoglobulin (at the same
concentration as for the antigen-specific antibody) was
used as a negative control. Staining for both antibodies
was performed at room temperature for 2 h. Biotinylated
goat antimouse serum IgG was used as a secondary anti-
body. After washing, the sections were incubated with
streptavidin-biotin conjugated with horseradish peroxi-
dase, and the peroxidase reaction was developed with 3,3’-
diaminobenzidine tetrahydrochloride. Counterstaining
with hematoxylin was performed and the sections were
dehydrated in ethanol before mounting.
Two independent blinded investigators examined all
tumor slides randomly. Five views were examined per
slide, and 100 cells were observed per view at 400 × mag-
nification. Immunostaining of δ-catenin was scored on a
semiquantitative scale by evaluating in representative
tumor areas the intensity and percentage of cells showing
significantly higher immunostaining than control cells in
normal brain tissues. Cytoplasmic immunostaining in
tumor cells was considered positive staining. We counted
400 tumor cells and calculated the percentage of posi-
tively stained cells. The proportion of cells exhibiting
δ-catenin expression was categorized as follows: 0,
absent; 1, 1-25%; 2, 26-50%; 3, 51-75%; and 4, ≥ 76%. The
staining intensity was categorized as follows: 0, negative;
1, moderate; and 2, strong. The proportion and intensity
scores were then multiplied to obtain a total score. To
obtain final statistical results, a score < 2 was considered
negative and scores ≥ 2 were considered positive.
Western blot analysis
Total proteins from tissue and cells were extracted in
lysis buffer (Pierce, Rockford, IL) and quantified using
the Bradford method. Samples of 50 μgo fp r o t e i nw e r e
separated by SDS-PAGE. Samples were transferred to
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MA, USA) and incubated overnight at 4°C with antibody
against δ-catenin (1:1000; Santa Cruz) and a mouse
monoclonal antibody against b-actin (1:500; Santa
Cruz). After incubation with peroxidase-coupled
antimouse IgG (Santa Cruz) at 37°C for 2 h, bound pro-
teins were visualized using ECL (Pierce) and detected
using a BioImaging System (UVP Inc., Upland, CA,
USA). Relative protein levels were quantified using b-
actin as a loading control.
Figure 1 Expression of δ-catenin in resected astrocytoma tissue. (A) HE staining of normal brain tissue. (B) Immunohistochemical staining of
δ-catenin protein in normal brain tissue was negative in glial cells and positive in neurons. (C) HE staining of pilocytic astrocytoma (grade I). (D)
Negative δ-catenin staining in pilocytic astrocytoma (grade I). (E) HE staining of grade II astrocytoma. (F) Positive δ-catenin staining (weak
staining) in the cytoplasm of grade II glioma. (G) HE staining of grade III astrocytoma. (H) Strong cytoplasmic δ-catenin staining in grade III
astrocytoma. (I) HE staining of glioblastoma (grade IV). (J) Strong cytoplasmic δ-catenin staining in glioblastoma (grade IV).
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U251 and U87 cells were transfected with siRNA or a δ-
catenin plasmid for 48 h andt h e np l a t e di n t ot h r e e6 -
cm cell culture dishes (1000 per dish) and incubated for
12 days. Plates were washed with PBS and stained with
Giemsa. The number of colonies with more than 50
cells was counted. The colonies were manually counted
using a microscope.
Cells were plated in 96-well plates in medium contain-
ing 10% FBS at approximately 3000 cells per well 24 h
after transfection. For quantitation of cell viability, cul-
tures were stained after 4 days in MTT assays. In brief,
20 μl of 5 mg/ml MTT (thiazolyl blue) solution was
added to each well and incubated for 4 h at 37°C. The
medium was removed from each well and the resulting
MTT formazan was solubilized in 150 μlo fD M S O .
Each solution was measured spectrophotometrically at
490 nm.
Matrigel invasion assay
Cell invasion assays were performed in 24-well Trans-
w e l lc h a m b e r sw i t hap o r es i z eo f8μm and the inserts
were coated with 20 μlo fM a t r i g e l( 1 : 3d i l u t i o n ,B D
Bioscience, San Diego, CA, USA). At 48 h after transfec-
tion, cells were trypsinized and transferred to the upper
Matrigel chamber in 100 μl of serum-free medium con-
taining 3 × 10
5 cells and incubated for 16 h. Medium
supplemented with 10% FBS was added to the lower
chamber as the chemoattractant. Then non-invading
cells on the upper membrane surface were removed
with a cotton tip and cells that had passed through the
filter were fixed with 4% paraformaldehyde and stained
with hematoxylin. The number of invaded cells were
counted in 10 randomly selected high-power fields
under a microscope. The experiments were performed
in triplicate.
Rac1 pulldown assayM
Rac1 activity was measured using a Active Rac1 Pull-
Down and Detection Kit (Pierce). The Rac1 inhibitor
NSC23766 was from Calbiochem (Merck, Whitehouse
Station, NJ, USA). Cells were treated for 6 h at a con-
centration of 50 μM.
Statistical analysis
SPSS version 11.5 for Windows was used for all statisti-
cal analyses. A c
2 test was used to examine possible
correlations between δ-catenin expression and clinico-
pathologic factors. Student’s t-test was used to compare
densitometry data on focus numbers between control
and δ-catenin-transfected cells. All p values are based
on a two-sided statistical analysis, and p < 0.05 was con-
sidered to indicate statistical significance.
Results
Expression and localization of δ-catenin in normal brain
tissue and astrocytoma cells
In cells from normal brain tissue, only neurons showed
strong cytoplasmic (include axon) expression of δ-catenin,
whereas glial cells showed no expression (Figure 1a, b).
Cytoplasmic staining was present in a subset of astrocy-
toma cases, while no staining was detected in sections
from the same samples subjected to immunohistochemical
analysis using mouse immunoglobulin. Of the 156 patients
in the study, 40 (25.6%) showed positive δ-catenin expres-
sion. δ-Catenin expression predominantly occurs in the
cytoplasmic compartment of tumor cells. We analyzed the
correlation between δ-catenin protein expression and the
histological staging of astrocytoma. As shown in Table 1
Grade I astrocytoma (0%, 0/11) and normal glial cells
exhibited negative staining (Figure 1c, d). In grade III-IV
astrocytoma (35%, 29/84; Figure 1g-j), δ-catenin expres-
sion was significantly higher than in grade II astrocytoma
Table 1 The relationship between δ-catenin and
clinicopathological features
Clinical parameters Number δ-catenin p value
Negative Positive
Age
< 43 78 61 17 0.359
≥ 43 78 55 23
Gender
Male 95 69 26 0.578
Female 61 47 14
Grading
Grade I 11 11 0 0.009*
Grade II 61 51 11
High Grade (III-IV) 84 55 29
* p < 0.05
Table 2 Association of δ-catenin expression with tumor
location
δ-catenin
Sites Total Negative Positive
Supratentorial
Hemisphere 124 87(70.2%) 37(29.8%)
Diencephalon 2 2(100%) 0(0%)
Total 126 89(70.7) 37(29.3%)
Infratentorial
Cerebellum 17 13(76.5%) 4(23.5%)
Brain stem 5 5(100%) 0(0%)
Spinal cord 8 8(100%) 0(0%)
Total 30 26(86.7%) 4(13.3%)*
* Supratentorial versus Infratentorial, p < 0.05
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catenin expression is associated with astrocytoma
progression.
W ee x a m i n e dt h ed i f f e r e n c eb e t w e e nt h ee x p r e s s i o n
pattern of δ-catenin according to tumor location. As
shown in Table 2 the positive rate of δ-cateninin supra-
tentorial astrocytomas was 29.3%, much higher than the
rate in infratentorial astrocytomas (13.3%). (p < 0.05).
δ-Catenin overexpression promotes astrocytoma cell
proliferation and invasion via Rac1
To determine whether δ-catenin enhances the prolifera-
tion and invasion of astrocytoma cells, we carried out δ-
catenin transfection in the U251 astrocytoma cell line.
siRNA knockdown was performed in the U87 glioblas-
toma cell line.
As shown in Figure 2, δ-catenin transfection consider-
ably increased protein levels at 48 h after treatment,
whereas δ-catenin siRNA knockdown decreased δ-catenin
protein in U87 cells. The proliferation rate was determined
by MTT assay. A significant increase in proliferation was
observed in U251 cells overexpressing δ-catenin compared
to cells transfected with the empty vector (Figure 3a).
Consistent with the MTT results, colony formation assays
showed that transfection of δ-catenin in U251 cells led to
an increase in focus numbers (empty vector 109 ± 23 vs δ-
catenin 174 ± 26, p < 0.05; Figure 3b). δ-Catenin also pro-
moted tumor cell invasion in a Matrigel assay (empty vec-
tor 55 ± 10 vs δ-catenin 73 ± 15, p < 0.05; Figure 4a). In
U251 cells overexpressing δ-catenin, immunoblotting
showed total Rac1 protein levels were unchanged, but a
pulldown assay revealed that Rac1 activity increased signif-
icantly (Figure 4b). Conversely, δ-catenin knockdown
decreased the proliferation, colony formation ability (con-
trol158 ± 21 vs siRNA δ-catenin 97 ± 17, p < 0.05; Figure
5) and invasiveness of U87 cells (control 59 ± 7 vs siRNA
δ-catenin 36 ± 5, p <0 . 0 5 ) .δ-Catenin knockdown also
decreased Rac1 activity (Figure 6).
Figure 2 δ-Catenin transfection of U251 cells and siRNA knockdown in U87 cells. Western blot and real-time PCR analyses showed that
U251 cells transfected with the δ-catenin plasmid expressed higher levels of δ-catenin. δ-Catenin expression in U87 cells transfected with siRNA
was downregulated.
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sion was dependent on Rac1 activity, we measured cell
invasion and Rac1 activity after treatment of δ-catenin-
transfected cells with the Rac1 inhibitor NSC23766. The
inhibitor abolished the effect of δ-catenin on cell invasion
(δ-catenin 73 ± 15 vs δ-catenin + Rac1 inhibitor 42 ± 9,
p < 0.05).
Discussion
δ-catenin plays an important role in dendritic morpho-
genesis, which is associated with changes in the activity
of small GTPases [7,13]. The formation and number of
dendritic protrusions are indicative of the malignant
phenotype of cells, so it is possible that δ-catenin pro-
motes a malignant phenotype in tumor cells. It has been
reported that δ-catenin expression was increased in over
80% (55/65) of prostatic adenocarcinomas, and was asso-
ciated with higher Gleason scores [4]. Some researchers
also observed gene amplification of δ-catenin in cervical
and bladder carcinoma. δ-catenin mRNA is probably pre-
sent in esophagus, ovary and breast tumors [17,18]. Our
previous study showed that δ-catenin was overexpressed
in non-small-cell lung cancer and was correlated with
clinicopathological factors [16]. However, the expression
pattern and clinical significance of δ-catenin are poorly
defined in other human cancers such as astrocytoma.
Figure 3 δ-Catenin transfection promotes cancer cell proliferation in U251 cells. (A) MTT assays were performed after δ-catenin
transfection. An increase in absorbance was observed. (B) Assessment of the clonogenic potential of δ-catenin-transfected glioma cells. The
number of colonies formed by cells treated with δ-catenin was greater than for control cells (p < 0.05). Columns, mean; bars, SD.
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glial cells prepared from fetal rat brain showed that δ-
catenin expression levels were higher in neurons than in
glial cells [19]. However, its p r o t e i ne x p r e s s i o ni nn e u -
rons and glial cells has not been investigated. In this
study, we found strong cytoplasmic δ-catenin expression
in neurons but negative staining in human glial cells such
as astrocytes, which may due to the low mRNA copy
numbers of δ-catenin. Although there was no expression
of δ-catenin in 11 grade I astrocytoma cases, positive δ-
catenin was found in 18% of grade II and 35% of grade
III-IV astrocytoma cases, which suggests that δ-catenin is
positively associated with higher grade astrocytoma. Posi-
tive rate of δ-catenin in low grade astrocytoma is very
low, especially in grade I astrocytoma (Negative
expression). and its utilization in the distinguishing grade
I astrocytoma from reactive gliosis was limited. The low
grade astrocytoma with positive δ-catenin expression
may transform into high grade astrocytoma. These find-
ings indicate that δ-catenin might play an important role
in astrocytoma progression and could serve as a potential
biomarker for the biological behavior of astrocytoma
cells.
To explore the relationship between δ-catenin and the
biological behavior of astrocytoma cells, we transfected a δ-
catenin plasmid into the U251 cell line, which has low δ-
catenin expression, and knocked down δ-catenin in the
U87MG cell line, which has high δ-catenin expression. We
found that δ-catenin overexpression caused a significant
increase in the proliferation rate, colony formation and
Figure 4 δ-Catenin knockdown inhibits proliferation in U87 cells. (A) MTT assays were performed after δ-catenin siRNA transfection. A
decrease in absorbance was observed. (B) Assessment of the clonogenic potential of δ-catenin-transfected glioma cells. The number of colonies
formed by cells treated with δ-catenin siRNA was less than for control cells (p < 0.05). Columns, mean; bars, SD.
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in Rac1 activity, which was in accordance with our previous
results for lung cancer [16]. On the contrary, δ-catenin
knockdown decreased the proliferation rate, colony forma-
tion ability and invasiveness of U87 cells, with a decrease in
Rac1 activity. We then observed a decrease in invasiveness
and Rac1 activity after treatment of δ-catenin-transfected
cells with a Rac1 inhibitor, which demonstrates that δ-cate-
nin regulates cell invasion in a Rac1-dependent manner.
These results suggest that δ-catenin might enhance the
invasive ability of astrocytoma cells via Rac1. However, the
exact mechanism of Rac1 regulation by δ-catenin is not
clear. In addition, previous studies proved that δ-catenin
has an influence in other small GTPases, such as Cdc42
and RhoA, which was not investigated in glioma cell lines
[13]. Further studies are required to address these issues.
Conclusion
In conclusion, overexpression of δ-catenin in astrocy-
toma cells was correlated with higher grade and δ-cate-
nin was identified as an important oncoprotein in
maintaining the malignant behavior of glioma cells.
Overexpression of δ-catenin activated Rac1 and pro-
moted astrocytoma cell proliferation and invasion. Thus,
δ-catenin is a candidate target protein for future astro-
cytoma therapeutics.
Figure 5 Invasion assay of cells transfected with δ-catenin and siRNA. δ-Catenin transfection promoted cell invasion in U251 cells, while
siRNA knockdown of δ-catenin had an inhibitory effect. The numbers of cells invading onto the lower surface of the filter was significantly
different (p < 0.05). Columns, mean; bars, SD.
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